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Injured adult neurons in the CNS fail to regenerate as quickly as juvenile neurons, partially as a result of a loss of intrinsic growth capacity and partially as a result of an inhibitory environment formed around the glial scar (Goldberg et al., 2002; Bouslama-Oueghlani et al., 2003; Blackmore and Letourneau, 2006) . The developmental decline of axon growth capacity is attributed to many factors, including loss of epigenetic regulation for transcription factors essential for regeneration-associated gene upregulation (Di Giovanni, 2009; Lindner et al., 2013) and reduced microtubule dynamics and transport in the mature neuron (Lin et al., 2011; Baas and Ahmad, 2013; Gumy et al., 2013) . After injury in axons, the conversion of locally stable microtubules into more dynamic microtubules is important for regeneration of the axon and growth cone formation (Erturk et al., 2007) . Microtubule dynamics and functions are attributed to a variety of reversible posttranslational modifications (Janke and Kneussel, 2010; Janke and Bulinski, 2011; Song and Brady, 2014) . The enzyme families of histone acetyl transferases (HATs) and histone deacetylases (HDACs) control acetylation and deacetylation, respectively, and give rise to an acetylation homeostasis that is necessary for a variety of cellular functions that can impact axon and dendritic growth (Janke and Bulinski, 2011; Trakhtenberg and Goldberg, 2012; Lindner et al., 2013) . Whereas histone acetylation opens up chromatin to allow more gene transcription, promoting roles in learning, memory, neuroplasticity, and neurodegeneration (Peleg et al., 2010; Schneider et al., 2013) , microtubule acetylation is associated with greater stability and is more prevalent in older neurons (Ferreira and Caceres, 1989) , which may explain their limited axon growth in regeneration. Increased microtubule acetylation may be associated with more sensitivity to severing proteins, such as katanin, that disrupt the microtubule array (Sudo and Baas, 2010) . Studies also show that HDAC5 and HDAC6 upregulated in a gradient along the distal axon by retrograde injury signals are important for sensory neuron regeneration in sciatic nerves Cavalli, 2012, 2014) .
Novel pharmacological inhibitors of HATs (HATis) and HDACs (HDACis) may provide a new therapy for augmenting axon growth after spinal cord injury (Di Giovanni, 2009; Lindner et al., 2013) . We observed the effects of HATis, anacardic acid (AA), cyclopentylidene-[4-(4 0 -chlorophenyl)thiazol-2-yl)hydrazine (CPTH2), HDACis, trichostatin A (TSA), and tubacin on axon growth and turning across inhibitory chondroitin sulfate proteoglycan (CSPG) borders. Additionally, this study examines the dose-dependent effects of each drug on neurite lengths in adult dorsal root ganglia (DRG) cultures and determines the optimal concentration to be used in these studies. We show that AA and CPTH2 promote axon growth independently of detectable effects on microtubules, whereas tubacin, which specifically inhibits the main deacetylase for tubulin, HDAC6 (Hubbert et al., 2002; Haggarty et al., 2003) , inhibited axon growth.
MATERIALS AND METHODS

DRG Neuron Culture
Sprague Dawley rats (50 g, 21 days old; Harlan, Tampa, FL) were euthanized, and DRGs were dissected. After a 60-min digestion in 0.25% collagenase at 37 C, the DRGs were mechanically dissociated by trituration and centrifuged. The dissociated neurons were resuspended in neurobasal A medium with B27 supplement and plated on a poly-D-lysine-coated glass coverslip (0.1 mg/ml) with no laminin. No neurotrophins were added to the plating medium to ensure that the observed effects were independent of trophic factor signaling. Six hours after plating, DRG cultures were treated with compounds AA, CPTH2, TSA, tubacin, or dimethylsulfoxide (DMSO; SigmaAldrich, St. Louis, MO) at various concentrations. For immunocytochemistry, the neurons were fixed with 4% paraformaldehyde with glutaraldehyde in PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, and 2 mM MgCl 2 ) for 10 min before blocking with 10% goat serum and 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 30 min and permeabilization with 0.1% Triton X-100. Fixed cells were incubated with monoclonal anti-bIII-tubulin antibody (1:1,000; Promega, Madison, WI), acetylated tubulin (1:200; Sigma-Aldrich), or a-tubulin (1:200, Thermo Fisher Scientific; Waltham, MA) at 4 C overnight. On the next day, the samples were rinsed three times with PBS before incubation with Texas red anti-rabbit IgG (1:400; Jackson Immunoresearch, West Grove, PA) and fluorescein isothiocyante anti-mouse IgG (1:400; Jackson Immunoresearch) at room temperature for 60 min. Images were taken of neurons labeled by bIII-tubulin and by acetylated tubulin. For quantification of neurite outgrowth, the length of all neurites for the first 20 neurons encountered was determined by tracing in the Neuron J plugin (www. imagescience.org) of ImageJ.
Microfluidic Chambers
DRG neurons were grown in microfluidic chambers after dissociation to isolate cell bodies from axons and growth cones with methods similar to those used in other laboratories (Liu et al., 2008; Kim et al., 2012) . Microfluidic chamber templates were designed in the Smith laboratory and fabricated at the Stanford Microfluidics Foundry (http://www.stanford.edu/ group/foundry/index.html). A two-layer mask design was drawn out in AutoCAD WS software (www.autodesk.com) at 20,000 dpi resolution, and alignment marks were drawn according to the specifications of the Stanford Microfluidics Foundry. Microchannels were designed to be 450 3 5 3 5 lm, and the pattern was repeated four times on a 100-mmdiameter circle (see Fig. 4A and B). Microfluidic chambers were cast by pouring Sylgard Silicone Elastomer 184 mix (Dow Corning, Midland, MI) onto microfluidic templates and were heated for 2 hr at 60 C before being cut out into shape. Neurons were cultured in microfluidic chambers in close proximity to a CSPG border so that axons extended toward the border (see Fig. 4B ). CSPG borders were prepared with a modification of a procedure previously used to repel chick DRG axons successfully (Snow et al., 2003) . Briefly, a strip of Whatmann filter paper was soaked in Aggrecan (500 lg/ml; Sigma-Aldrich) and was laid on glass coverslips for 30 min before being removed. Coverslips were then coated in laminin (10 lg/ml; SigmaAldrich) and incubated until neurons were ready to be plated. Inhibitors were added to the cell body chamber, to the axon chamber, or to all the chambers, and the cells were left to grow for an additional 4 days before being fixed with paraformaldehyde to assess their ability to grow across the CSPG border. The cultures were labeled with bIII-tubulin, an axon marker, and CS-56, an antibody directed against CSPGs. Quantification was carried out for the success rate of axon crossing after each treatment.
Western Blotting
DRG neurons were harvested from culture dishes after incubation with HATis and HDACis. The cells were lysed in 0.5% Triton X-100, 3% sodium dodecyl sulfate (SDS), 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 1 mM EDTA containing protease inhibitors and phosphatase inhibitor. To carry out histone extraction, a Triton extraction buffer was used, consisting of 0.5% Triton X-100, 2 mM phenylmethylsulfonyl fluoride (PMSF), 0.02% NaN 3 , 5 mM sodium butyrate, and PBS. Cells were lysed on ice for 10 min before centrifugation at 6,500g for 10 min to spin down nuclei. Nuclei were resuspended in 10 N HCl. Equal quantities of total protein were loaded onto a 15% polyacrylamide gel and transferred to a nitrocellulose membrane (Amersham Pharmacia, Piscataway, NJ). After having been blocked in 5% milk for 1 hr at room temperature, the blots were incubated with antiacetylated tubulin 6-11-b1 (1:1,000; Sigma-Aldrich), anti-bIII-tubulin (1:500; Promega), anti-a-tubulin (1:10,000; Thermo Fisher Scientific), antihistone H3 (1:500; Cell Signaling Technology, Danvers, MA), or antiacetylated histone H3 (1:200; Active Motif, Carlsbad, CA) overnight at 4 C. The corresponding conjugated secondary antibodies donkey anti-rabbit IRDye-800CW and goat anti-mouse IRDye-680CW (1:20,000; LI-COR Biosciences; Lincoln, NE) were added on the next day and incubated for 1 hr at room temperature before being washed three times for 15 min in Tris-buffered saline (TBS)-Tween. Fluorescent blots were imaged on an Odyssey infrared imaging system (LI-COR Biosciences), and Western blots were processed with ECL. The corresponding secondary antibodies goat anti-rabbit HRP and goat anti-mouse HRP (1:10,000; Cell Signaling Technology) were added after a 1-hr primary antibody incubation at room temperature. Blots were washed three times for 15 min each in TBS-Tween before incubation in ECL Prime Western blotting detection agent (GE Healthcare, Piscataway, NY) for 5 min and were exposed under GeneMate Blue Lite X-ray film (BioExpress, Kaysville, UT) in the dark for film development.
Statistical Analysis
Raw data were processed, statistical analyses were performed, and graphs and charts were produced in Graphpad Prism 6. All data for image analysis of axon lengths, for axon crossing of CSPG borders, and for Western blotting densitometric quantifications were tabulated, and statistical analysis was by one-way ANOVA, followed by the Tukey post hoc test to determine significant differences between groups. Data are mean 6 SEM. P < 0.05 was considered significant.
RESULTS
HATis and HDACis Have a Dose-Dependent Effect on Axon Length
Although there is evidence that HATis may be important for neuroprotection (Egawa et al., 2012) , no one has studied the effects of HATis on axon growth or regeneration. A range of inhibitor concentrations was tested for each compound before the investigation began to determine the optimal concentration for maximum axon growth and to ensure that there were no toxic effects on neuronal survival. The effect of varying concentrations of AA in cultured adult DRG neurons was tested. The length of the longest axon increased progressively as the concentration of AA increased. The mean longest axon length in cultures treated with 1 mM AA (313 6 28.4 lm) was significantly greater than the mean longest axon length in cultures treated with 5 pM AA, (164.7 lm 6 14.4, P < 0.001; Fig. 1A ). The mean total axon length progressively increased with increasing concentration up to 10 nM (812 6 95 lm), maintaining similar lengths with higher concentrations of AA (Fig. 1B) .
CPTH2 is an inhibitor of the HAT Gcn5 in cancer cells (Sar et al., 2011) , but it has never been tested in neuronal cultures. In neurons treated with CPTH2, the mean length of the longest axon peaked in cultures treated with 50 nM (252.9 6 40 lm) and progressively declined with higher concentrations (Fig. 1C) . The mean total length of axons followed a similar dose-response pattern (Fig. 1D ), peaking at 50 nM (709.7 6 138.1 lm) and decreasing in length with higher CPTH2 concentrations to 500 lM (49.8 6 7.8 lm, P < 0.01).
Tubacin is a potent inhibitor of HDAC6 activity, preventing a-tubulin acetylation (Haggarty et al., 2003) , and it has been used at up to 20 lM in neurons . In neurons treated with tubacin, the mean length of the longest axon progressively decreased to 100 6 13 lm as concentration increased to 10 lM but reverted back to longer lengths (192.3 6 22.3 lm, P < 0.05) as concentration increased to 50 lM (Fig. 1E) . Similarly, the mean total axon length for tubacin-treated neurons reached a minimum at 10 lM (240.2 6 32.9 lm) before increasing again at 100 lM (380 6 53.5 lm; Fig.  1F ). Recent evidence suggests that tubacin can inhibit many different HDACs at higher concentrations and that tubastatin A is a more specific inhibitor of HDAC6 (Butler et al., 2010) . We treated neurons with either tubastatin A or tubacin at 1 lM and found similar axon lengths with both inhibitors. Increases in tubastatin A concentration to 2 lM and 5 lM also reduced the level of axon growth, as did longer incubation periods of the drug over 24 hr (data not shown).
TSA is a nonspecific inhibitor of class II HDACs that has previously been used at 10-300 nM in cultured neurons, resulting in improved axon growth (Rivieccio et al., 2009; Gaub et al., 2010 Gaub et al., , 2011 . The mean longest axon length was highest at the lowest TSA concentration tested (50 nM TSA; 238.7 lm 6 16.9, P < 0.05), declining to 300 nM TSA (66.4 6 17.9 lm) and leveling off at higher concentrations (Fig. 1G ). The total mean axon lengths showed an unusual pattern ( Fig. 1H) , with increased TSA concentrations peaking at 50 nM TSA (579 6 44.6 lm) and decreasing at 300 nM TSA (280.7 6 37.5 lm, P < 0.001). Neurite outgrowth increased again at 50 lM (485.8 6 58.6 lm) before declining at a concentration of 1 mM TSA (380 6 49.5 lm, P < 0.05). There were no dramatic differences in neuronal viability among the cultures for the different concentrations of compounds in this study, although neuronal survival was lower with the highest concentrations tested.
HAT Inhibitors Increase Axon Length, Whereas HDAC Inhibitors Decrease Axon Length, in Cultured Adult DRG Neurons
HATs regulate acetylation, and HDACs regulate deacetylation (Janke and Bulinski, 2011; Lindner et al., 2013; Trakhtenberg and Goldberg, 2012) . It is possible that inhibition of HATs could have an effect on axon growth opposite to that of the inhibition of HDACs. To test this hypothesis, HATis and HDACis were added to cultured DRG neurons at concentrations similar to those described elsewhere (Rivieccio et al., 2009; Chen et al., 2010; Sudo and Baas, 2010; Sar et al., 2011; Egawa et al., 2012) . Inhibitors were incubated for 48 hr to ensure that drugs would have sufficient time to affect outgrowth. After exposure to the compounds, the length of the longest axon in each neuron treated with AA (602.4 6 39.9 lm, P < 0.05) and CPTH2 (618.4 6 33.2 lm, P < 0.05) was significantly greater than the length of the longest axon in each neuron treated with control DMSO (422.8 6 42.5 lm). Also, treatment with TSA (68.1 6 20.5 lm, P < 0.001) and tubacin (98.8 6 13.0 Fig. 1 . Changes in concentrations of HATis and HDACis affect axon growth in adult DRG neurons. Dissociated DRG neurons were grown in the presence of HATis and HDACis for 24 hr at varying concentrations before being fixed in paraformaldehyde and labeled with bIII-tubulin A: AA was added at a range of concentrations (5 pM, 5 nM, 10 nM, 5 lM, 10 lM, and 1 mM). Images were taken of the first 20 neurons observed under the microscope, and the lengths of all processes from neurons were measured. As AA concentration increased, there was a progressive increase in the mean of the longest axon lengths, with the longest axons observed after 1 mM AA treatment. B: Similarly, the mean length of total axons increased with increasing AA concentration, but the greatest axon growth was seen with 10 nM AA treatment. C: CPTH2 was added at a range of concentrations (50 pM, 10 nM, 50 lM, 100 lM, and 500 lM). As CPTH2 concentration increased, there was a progressive decrease in the mean of the longest axon lengths. The mean of the longest axon lengths was longest when treated with 50 nM. D: Similarly, the mean of the total axon lengths was observed with 50 nM CPTH2 treatment. E: Tubacin was added at a range of concentrations (10 pM, 10 nM, 10 lM, 20 lM, 50 lM, and 100 lM). The mean of the longest axon lengths was the shortest under the treatment with 10 lM tubacin. At all other concentrations, the mean lengths of axons were longer. F: Similarly, the mean of the total axon lengths was shortest under treatment with 10 lM tubacin. G: TSA was added at a range of concentrations (50 nM, 300 nM, 50 lM, and 1 mM). The mean of the longest axon lengths decreased as TSA concentration increased, with the shortest axons growing at 300 nM treatment. H: The mean of the total axon lengths also decreased as TSA concentration increased, with the shortest axons growing at 300 nM treatment. *P < 0.05, **P < 0.01, ***P < 0.001. lm, P < 0.001) reduced the growth of the longest axon considerably compared with control DMSO treatment ( Fig. 2A,B) . Because many of the neurons elaborated multiple neurites, total neurite outgrowth from treated neurons was also measured. The mean total axon outgrowth in cultures treated with AA (1,872.7 6 230.9 lm, P < 0.01) but not CPTH2 (1,156.3 6 94.3 lm) was significantly higher than DMSO controls (1,135.3 6 125.5 lm). However, treatment with TSA (97.9 6 26 lm, P < 0.01) or tubacin (234.5 6 43.8 lm, P < 0.01) resulted in significant reductions in mean total length compared with DMSO control. To better identify the distribution of neurons showing differential growth within each treatment group, neurons were categorized and binned according to specific lengths (Fig. 2C) . In the control DMSO treatment, 41% and 47% of neurons had a greatest axon length of between 0 and 400 lm and 400 and 800 lm, respectively. Only 11.8% of neurons grew axons longer than 800 lm. However, among neurons treated with AA, 76.2% of neurons had a greatest axon length between 400 and 800 lm, with 9.5% growing axons longer than 800 lm. In cultures treated with CPTH2, 75% of neurons grew the longest axons 400-800 lm, with 10% growing axons longer than 800 lm. In neurons treated with TSA and tubacin, no neurons grew the longest axon greater than 400 lm. With respect to total axon lengths, 33.3% of neurons treated with DMSO grew axons less than 1,000 lm, 60% of neurons grew axons between 1,000 and 2,000 lm, and only 6% of neurons grew axons that totaled more than 2,000 lm. In neurons treated with AA, Fig. 2 . The HATis AA and CPTH2 significantly increase axon growth, whereas HDACis TSA and tubacin significantly decrease axon growth. Dissociated DRG neurons were grown in the presence of 10 lM AA, 50 nM CPTH2, 10 lM tubacin, or 300 nM TSA for 48 hr before being fixed and labeled with bIII-tubulin. A: Representative images of neurons labeled for bIII-tubulin antibody show all the axons emerging from the cell body. B: In neurons treated with AA, the mean lengths of the longest axon and the total axon lengths were significantly longer than with control neurons treated with DMSO. In neurons treated with CPTH2, only the mean length of the longest axon was significantly greater than that of neurons treated with DMSO. The mean total axon length was not different from control DMSO. In neurons treated with TSA and tubacin, the mean axon lengths and total axon lengths were less than those in neurons treated with DMSO. C: In neurons treated with AA and CPTH2, a greater proportion of neurons grew their longest axons between 400 and 800 lm compared with DMSO control. In neurons treated with AA, a greater proportion of neurons grew total axon lengths that reached over 2,000 lm compared with control. In neurons treated with CPTH2, there was little difference in the total axon lengths vs. neurons treated with DMSO. In neurons treated with TSA and tubacin, no axons were able to grow beyond 400 lm by the end of the experiment. *P < 0.05, **P < 0.01, ***P < 0.001. 42% had axons between 1,000 and 2,000 lm, 15.7% between 2,000 and 3,000 lm, and another 15.7% more than 3,000 lm. In CPTH2-treated cultures, 35% of neurons grew axons a total of less than 1,000 lm, and 65% of neurons grew axons between 1,000 and 2,000 lm. In TSA and tubacin-treated cultures, all neurons failed to grow axons a total of more than 1,000 lm. These data suggest that application of HATis AA and CPTH2 promotes axon growth, whereas HDACis, TSA, and tubacin decrease axon growth at specific concentrations.
Taxol Does Not Affect Axon Growth in Adult DRG Neurons
There is evidence that taxol, a compound known to stabilize microtubules, can promote axon growth in optic nerves and in the spinal cord after injury in vivo (Hellal et al., 2011; . However, there is controversy over whether taxol treatment and excessive stabilization of microtubules make sense as a means for enhancing axon regeneration (Baas and Ahmad, 2013) or whether they can even promote functional axon reinnervation after spinal cord injury (Popovich et al., 2014) . To test the effect of microtubule-stabilizing and -destabilizing drugs, taxol (10 nM) and nocodazole (300 nM) were applied to cultured DRG neurons. These concentrations were chosen from results observed by others in cultured neurons in vitro Charoenkwan et al., 2013) . Measurement of the longest axon lengths and total axon lengths of each neuron showed no significant difference between taxol (mean total length 1,301.7 6 232.1 lm, mean longest length 469.3 6 40.2 lm) and control DMSO treatments (mean total length 1,135.3 6 125.5 lm, mean longest length 422.8 6 42.5 lm). However, nocodazole significantly decreased the total length (254.1 6 66.9 lm) and longest length (112.9 6 18.8 lm) of neurons following the treatment compared with control groups (Fig. 3A) . Neurons were categorized into groups according to axon lengths, and the neurons that were distributed in each group were counted for each of the treatments (Fig. 3B) . In cultures treated with taxol, equal numbers of neurons grew their Fig. 3 . Taxol and nocodazole do not affect axon growth in adult DRG neurons. Dissociated DRG neurons were grown in the presence of taxol, a microtubule-stabilizing compound, and nocodazole, a microtubule-depolymerizing compound, for 24 hr and fixed. Neurons were labeled for bIII-tubulin antibody, and images of axons were quantified. A: The mean longest and total axon length of neurons treated with nocodazole was significantly different from that of neurons treated with DMSO. The mean longest and total axon length of neurons treated with taxol was not significantly different from that of neurons treated with DMSO. B: After treatment with nocodazole, the proportion of neurons with mean axons longer than 400 lm was just over 10%, whereas treatment with taxol resulted in a roughly equal number of neurons growing axons below and above 400 lm. After treatment with nocodazole, the mean of total axon lengths between 1,000 and 2,000 lm was also just over 10%, and the same was true for axon lengths between 2,000 and 3,000 lm. After treatment with taxol, nearly 40% of neurons grew a total axon length between 1,000 and 2,000 lm. Some neurons grew axons of more than 3,000 lm. *P < 0.05, **P < 0.01. longest axon between either 0 and 400 lm or 400 and 800 lm. In neurons treated with nocodazole, 85.7% of neurons grew the longest axon less than 400 lm. With respect to total axon lengths, in cultures treated with taxol, 52.6% of neurons grew axons less than 1,000 lm, 36.8% of neurons grew axons between 1,000 and 2,000 lm, 5.3% of neurons grew axons between 2000 and 3000 lm, and 5.3% of neurons grew axons over 3,000 lm. However, in nocodazole-treated cultures, 75% of neurons grew axons a total of less than 1,000 lm, 12.5% of neurons grew axons between 1,000 and 2,000 lm, and another 12.5% of neurons grew axons between 2,000 and 3,000 lm. When taxol was combined with HATis and HDACis, no significant changes in axon lengths were observed compared with HATi or HDACi treatment alone in cultured adult DRG neurons (data not shown). The fact that the total axon length decreased in the presence of nocodazole is in agreement with evidence that nocodazole prevents microtubule polymerization, and a loss of microtubule mass correlates with less axon outgrowth (Baas and Heidemann, 1986; Baas et al., 1993) .
HATis Improve Axon Crossing of CSPG Borders
To test the potential effect of HATis and HDACis on axon regeneration, their effects on DRG neurons growing toward an inhibitory CSPG border in vitro were examined. CSPGs are commonly found at the glial scar following injury and present a challenge to the regenerative capacity of axons, often causing them to form dystrophic, stalled growth cones (Hynds and Snow, 1999; Tom et al., 2004) . We used a microfluidic chamber assay to study axon regeneration in an in vitro model because these devices can be easily controlled to manipulate cellular environments (Taylor et al., 2005; Liu et al., 2008; Hur et al., 2011; Kim et al., 2012) . Neurons were cultured in microfluidic chambers in close proximity to a CSPG border (stripe) so that axons extended toward the border ( Fig. 4B ; see Materials and Methods). Experiments were repeated five times for each treatment to examine statistical significance. Compounds were applied to all of the chambers. Application of AA promoted nearly tenfold more axons (49.8% 6 18.7%, P < 0.01) to cross the CSPG border compared with neurons grown in DMSO control; CPTH2 also promoted more axons (12.8% 6 4.7%) to cross than DMSO control (5.5% 6 1.3). Application of TSA and tubacin decreased the number of axons that crossed the border (TSA 2% 6 1.9%, tubacin 0.95% 6 0.7%), and the number of axons that stopped or turned at the border increased compared with DMSO treatment (Fig. 4C and D) .
The HATi AA Acts on the Soma Compartment but Not on the Axon Compartment To Improve Axon Crossing of CSPG Borders
To test where in the neuron HATis and HDACis could be exerting effects on axon growth, DRG neurons growing in microfluidic chambers were treated with AA, CPTH2, tubacin, or TSA in either the cell body compartment or the axon compartment. When AA was applied to the cell body compartment, 26.5% 6 1.9% (P < 0.01) of axons crossed the CSPG border, a significant increase compared with DMSO control (3.2% 6 0.9%) and with AA treatment in the axon compartment (3.2% 6 1.8%; Fig. 5A,C) . This suggests that AA acts strongly at the cell body and not at the axon shaft of neurons to promote axon crossing of inhibitory CSPG borders. When CPTH2 was applied to the cell body compartment, 14.9% 6 4.6% of axons crossed the CSPG border, and, when CPTH2 was applied to the axon compartment, 15.5% 6 4.9% of axons crossed the CSPG border (Fig. 5A ). Although this proportion was more than that of the DMSO control, there was no statistically significant increase and no significant difference between the two cell chamber compartments. This suggests that CPTH2 does not act strongly in either the cell body or the axon shaft of axons but does promote axon crossing of CSPG borders to a lesser extent than AA. Application of TSA and tubacin in either the soma or the axon compartment of microfluidic chambers showed no difference in axon crossing of CSPG borders (Fig. 5B) . Application of TSA in the cell body compartment caused only 3.2% 6 1.4% axon crossing, and in the axon compartment it resulted in only 2.6% 6 1.3%. Application of tubacin in the cell body compartment resulted in 9% 6 5.2% axon crossing, and in the axon compartment it resulted in 2% 6 1.3%.
HDACis Increase Microtubule Acetylation in DRG Neurons, but HATis Have Little Effect on Microtubules
To test whether the effects of HATis and HDACis on axon growth are due to changes in acetylation of microtubules or to acetylation of histones, cultured DRG neurons were treated with inhibitors or with DMSO for 48 hr, lysed, and collected for Western immunoblotting. Samples were probed with acetylated tubulin antibody, total tubulin antibody, acetylated histone H3 antibody, and total histone H3 antibody. Densitometric intensities of acetylated tubulin were ratioed against total a-tubulin (Fig. 6A and B) , and ratios were normalized to cultures treated with DMSO control. Quantification of Western blots showed that, in cultures treated with AA and CPTH2, acetylated tubulin did not change significantly with respect to control cultures treated with DMSO. In cultures treated with tubacin, the level of acetylated tubulin increased relative to all other treatments, and this rise was significant (12.1% 6 6.5%, P < 0.05) compared with DMSO control. In cultures treated with TSA, acetylated tubulin did not increase when ratioed against total atubulin. In summary, these data suggest that HATis do not inhibit tubulin acetylation, whereas the HDACi tubacin increases tubulin acetylation under the experimental conditions of this study. In cultures treated with AA and CPTH2, acetylated H3 was reduced relative to all other treatments (Fig. 6C,D) . Densitometric intensities of acetylated H3 were ratioed against total H3. Quantification of these Western blots showed that treatment with AA and CPTH2 reduced the level of acetylated H3, but reduction was not significantly lower than with DMSO control. Treatment with TSA and tubacin did not significantly change with respect to control cultures treated with DMSO. This shows that HATis but not HDACis strongly block histone acetylation.
To test whether HDACis and HATis affect the expression of acetylated tubulin along the length of the axon, cultured DRG neurons treated with inhibitors were fixed and immunolabeled with acetylated tubulin and a-tubulin antibody. Densitometric intensities of acetylated tubulin were ratioed against total a-tubulin for each neuron (n 5 8), and each axon was divided into Fig. 4 . Neurons treated with HATis grow over inhibitory CSPG borders in microfluidic chambers, whereas neurons treated with HDACis turn at the border. Dissociated DRG neurons were plated into microfluidic chambers and allowed to grow axons toward a CSPG stripe. Cultures were fixed after 5 days of growth and labeled with tubulin (green) and with CS-56 antibody (red) A: Microfluidic chambers were cast by pouring silicone elastomer into a prefabricated microfluidic template, and holes were punched to mark the chambers (see Materials and Methods). B: Microfluidic chambers were placed over a CSPG stripe before neurons were plated into a small hole and allowed to occupy the cell body chamber. Neurons were grown for 5 days until axons reached the CSPG stripe. C: In neurons treated with AA, significant proportions of axons were able to cross the CSPG border compared with neurons treated with DMSO. In neurons treated with CPTH2, more axons were able to cross the CSPG border compared with neurons treated with DMSO, but this proportion was less compared with DMSO. In neurons treated with TSA and tubacin, very few axons were able to cross the CSPG border. **P < 0.01. Fig. 5 . The HATi AA acts on the cell body compartment but not the axon compartment to promote axon crossing over inhibitory CSPG barriers. Dissociated DRG neurons were plated in microfluidic chambers and allowed to grow axons toward the inhibitory border. Cultures were fixed after 5 days of growth and labeled with tubulin (green) and with CS-56 antibody (red). A: AA and CPTH2 were added to the cell body chamber (cell body) or to the axon chamber on the side proximal to the CSPG stripe (axon) and compared with cultures treated with DMSO. B: TSA and tubacin were added either to the cell body or to the axon compartment. C: In cultures in which AA was added only to the cell body, a significantly greater proportion of axons crossed the CSPG border. In cultures in which CPTH2 was added, more axons crossed the CSPG border relative to DMSO control, but the numbers were not significant. In all other treatments, axons were not able to cross the inhibitory CSPG border to a greater extent than DMSO control. **P < 0.01. seven segments, with 1 representing the most proximal end and 7 representing the distal end (Fig. 7A,B) . The ratio of acetylated tubulin diminished compared with atubulin toward the distal end of axons in neurons treated with DMSO control, AA, and CPTH2. However, in neurons treated with TSA, the ratio of acetylated tubulin to a-tubulin did not diminish dramatically, and in neurons treated with tubacin this ratio increased toward the distal end of axons. This suggests that HATis have no effect on acetylated tubulin distribution in the axon but that HDACis increase acetylated tubulin in the distal axon.
DISCUSSION
This study shows for the first time that HATis increase axon growth in adult DRG neurons and promote axon crossing of inhibitory CSPG borders in vitro, whereas HDACis have the opposite effect, inhibiting axon growth and limiting the capacity of axons to cross CSPG borders. The two HATis used in this study, AA and CPTH2, are allosteric noncompetitive inhibitors of p300/CBP and Gcn5, respectively (Song et al., 2010; Hemshekhar et al., 2011; Sar et al., 2011; Egawa et al., 2013) . Although AA is known to play a role in dopaminergic neuronal survival, the effects of CPTH2 on axon growth are Fig. 6 . HDACi tubacin increases microtubule acetylation, whereas HATis moderately decrease histone acetylation. A,B: Western immunoblots of lysates from adult DRG neuronal cultures treated with DMSO, AA, CPTH2, TSA, or tubacin for 48 hr were probed with acetylated tubulin antibody (6-11-b-1) and with a-tubulin antibody. Blots were developed with a LI-COR Odyssey system. Densitometric ratio of acetylated tubulin was ratioed against densitometric ratio of total a-tubulin. In lysates treated with AA, acetylated tubulin did not change compared with controls treated with DMSO. In lysates treated with CPTH2 and TSA, acetylated tubulin increased, but the increase was not significant. In lysates treated with tubacin, acetylated tubulin increased compared with controls. C,D: Western immunoblots of lysates from adult DRG neuronal cultures were probed with acetylated histone H3 antibody and with total histone H3 antibody. Blots were developed with ECL and exposed to X-ray film. Densitometric ratio of acetylated histone H3 was ratioed against densitometric ratio of total histone H3. In lysates treated with AA and CPTH2, acetylated histone H3 decreased compared with controls treated with DMSO, but no significant difference was observed. In lysates treated with tubacin and with TSA, acetylated histone H3 remained unchanged compared with controls. *P < 0.05. unknown. Previous studies have shown that downregulation of HATs, such as p300/CBP, Gcn5, and PCAF, is detrimental for neuronal development, neurodegenerative diseases, and cognitive ability (Schneider et al., 2013; Valor et al., 2013) . However, such studies focused only on the function of HATs in the nucleus to modify transcriptional mechanisms. The fact that HATs such as elongator proteins (ELP1 and ELP3) can also be expressed in the axoplasm, affecting tubulin acetylation, suggests that there are other functions of HATs outside the nucleus that are yet to be explored (Creppe et al., 2009; Nguyen et al., 2010; Creppe and Buschbeck, 2011) . Therefore, from the results of this study, the use of HATis to enhance axon growth in mature DRG neurons provides a possible novel avenue for augmenting axon regeneration after injury.
Although the HATis used in this study were shown to inhibit histone acetylation, no changes were observed in microtubule acetylation levels. Furthermore, because AA had a greater effect on axon crossing of the inhibitory CSPG border when applied to the cell body compartment than when applied to the axon compartment, this suggests that HATis exert a positive effect on axon growth by acting in the cell body. The multiple functions of HATs in neuronal growth are complicated and remain to be explored. Other proteins, such as the a-tubulin acetyltransferase, known to bind directly to microtubules, may play a role in the acetylation homeostasis and microtubule stability in neurons (Akella et al., 2010; Kalebic et al., 2013) . Moreover, many other microtubule posttranslational modifications could be at play in regenerating adult neurons, complicating the results observed with HATis Fig. 7 . HATis do not affect acetylated tubulin distribution in axons, and HDACis increase acetylated tubulin in the distal axon. A: Representative images of DRG axons treated with DMSO, AA, CPTH2, TSA, or tubacin for 48 hr before being fixed and labeled with a-tubulin antibody (green) and 6-11-b1 antibody (red). B: Ratio of acetylated tubulin relative to a-tubulin along the length of axons (n 5 8), with 1 representative of the proximal end of the axon and 7 representative of the distal end of the axon. (Song and Brady, 2014) . More in-depth studies are required to deduce the exact HDAC and HAT family members involved in axon growth.
The two HDACis used in this study were TSA, a nonspecific inhibitor of several HDACs (Matsuyama et al., 2002; Chang et al., 2009; Zilberman et al., 2009) , and tubacin, a specific inhibitor of HDAC6 (Haggarty et al., 2003) , an enzyme that deacetylates tubulin (Hubbert et al., 2002) . Previous studies have shown that downregulation of HDACs with TSA can boost axon growth in vitro and promote optic nerve and sensory neuronal regeneration in vivo (Rivieccio et al., 2009; Gaub et al., 2010 Gaub et al., , 2011 Lindner et al., 2013) . Although such studies have focused on the effects of HDACs in the nucleus that suppress growth-associated gene expression, they did not investigate the role of HDACs in the axon. The results from the current study on tubacin and TSA show that axon growth is inhibited and that tubulin acetylation (in particular with tubacin) is increased in these axons. In this study, the more potent HDAC6 inhibitor tubastatin A also caused a decrease in axon growth similar to tubacin. This suggests that microtubule deacetylation plays a role in axon growth. The current data are in agreement with a study showing that HDAC5 might play a positive role in neuronal regeneration when exported out of the nucleus by deacetylating microtubules in a gradient towards the growth cone (Cho and Cavalli, 2012; Cho et al., 2013) . One explanation might be that deacetylated tubulin in the axon has a different binding affinity for certain molecular motors and that this can impact features of axon transport (Reed et al., 2006; Hammond et al., 2010) . Another explanation is that highly acetylated microtubules, prone to severing by katanin, would disturb the optimal balance between long and short microtubules in developing neurons undergoing axon growth (Sudo and Baas, 2010) , which would be detrimental for axon growth. Further work is required to establish the effect of tubulin deacetylation on microtubule transport and polymerization in adult DRG neurons. It is of interest that application of taxol, a microtubule-stabilizing drug reported to augment axon regeneration in vitro and in vivo (Hellal et al., 2011; , failed to enhance axon growth in our experimental paradigms. This shows that stabilization of microtubules per se does not promote axon growth and that previous observations of the benefits of taxol on neuronal regeneration might have been due primarily to effects on the glial scar.
The results of the current study seem contrary to results from Gaub et al. (2010 Gaub et al. ( , 2011 ; this may be for a variety of reasons, including the use of different concentrations of TSA inhibitors and the use of different neuronal culture models. The current study is the first to investigate the effects of varying HATi and HDACi concentrations on axon lengths in cultured adult DRG neurons. The current results with TSA show that the 300 nM treatment significantly inhibited axon growth, whereas other concentrations resulted in varying effects on growth. However, Gaub et al. (2010) showed that concentrations of greater than 1 nM TSA in cerebellar granule neurons caused toxicity. Thus, a higher concentration of TSA used on DRG cultures might explain why axons failed to grow longer. Furthermore, given the variability in axon growth with different inhibitor concentrations, measurements of values for the mean longest axon lengths resulted in smaller changes relative to comparisons between mean total axon lengths of axons. Such considerations should also be taken into account in comparisons with data from Gaub et al. (2010) . On the other hand, our results with tubacin and tubastatin A, more specific inhibitors of HDAC6, show that axon growth is more limited at 1 lM tubastatin A, which is in agreement with the results found by others (Tapia et al., 2010) . This suggests that the effects of tubacin on axon growth are due to tubulin acetylation.
The use of inhibitors may have complicated observations in this study by affecting global gene expression changes. AA is an anticancer, fungicide, and bactericide compound known to inhibit many proteins other than the HATs, including Src family kinases, nuclear factorjB, xanthine oxidase, lipoxygenase, and tyrosinase (Eliseeva et al., 2007; Hemshekhar et al., 2011; Wu et al., 2011) . The inhibition of such proteins could result in a variety of changes to cell signaling activity that could increase axon growth. It may also explain why acetylated H3 is not significantly downregulated after AA and CPTH2 treatment. Studies have shown that TSA can induce neuronal apoptosis and that overexpression of the HAT cAMP response elementbinding protein can lead to neuronal cell death (Rouaux et al., 2003) by chromatin fragmentation in cerebellar granule neurons. Therefore, using HATis and HDACis can upset the delicate balance of histone acetylation in neurons, causing detrimental changes.
